Real-World Evidence and
Health Economics Outcomes Research
Congress Materials
2026: Real-World Comparative Effectiveness of Semaglutide 2.4 mg Versus Other Commercially Available Medications for Chronic Weight Management in Adults With Obesity in the United States: A Pragmatic Clinical Study Results from POSEY
2025: Utilizing a composite number needed to treat to assess the clinical and economic value of semaglutide and dulaglutide in populations with established cardiovascular disease
2025: Clinical characteristics and healthcare resource utilization among patients initiating semaglutide 2.4 mg versus those not treated with anti‑obesity medications
2025: Changes in HbA1c and Body Weight in US Adults with Type 2 Diabetes and Chronic Kidney Disease Who Received Oral Semaglutide
2025: Real-world clinical and demographic characteristics associated with progression to type 2 diabetes in patients with prediabetes
2025: Healthcare Utilization and Costs in Users of Once-Weekly GLP-1 Receptor Agonists vs Other Glucose-Lowering Therapies Among Medicare Beneficiaries With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease
2025: Healthcare resource utilization and costs in individuals who discontinue liraglutide and who switch from liraglutide to once-weekly injectable semaglutide
Liver Health
2026: A U.S.-Specific Budget Impact Model (BIM) of Semaglutide 2.4 mg in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Using Most-Favored-Nation (MFN) Pricing
2026: Cost-Effectiveness of Semaglutide 2.4 mg Compared with Resmetirom and Standard of Care for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in the U.S. Using Most-Favored-Nation (MFN) Pricing
2025: Patterns in Provider Specialties and Adoption of Noninvasive Tests for Diagnosing Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Hemoglobinopathies
2026: Association of fatigue and acute pain with health care resource utilization and costs in sickle cell disease in the United States
Search Novo Nordisk Medical
Novo Nordisk Medical is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products. It provides evidence-based information on a variety of topics important to patient care. All information is for educational purposes only and is not intended to promote any products.
Find more information
Find product information
Explore our portfolio of products for treating obesity, including prescribing information, safety data sheets and storage and stability information.
Continuing education
Learn about accredited obesity education opportunities supported by Novo Nordisk and provided by third-party organizations.
The purpose of this site is to provide relevant medical and scientific information about Novo Nordisk products and areas of therapeutic interest. Information about investigational products or investigational uses of approved products neither implies FDA approval for these products or uses, nor establishes the safety or efficacy of these products or uses. There is no guarantee that any investigational product or investigational use will receive FDA approval or become commercially available in the United States. Novo Nordisk does not recommend or suggest use of its products in any manner inconsistent with FDA-approved labeling.
This site is intended for United States healthcare professionals only. The information on this site—including all product information—pertains to residents of the United States only. Any products referenced on this site may have different labelling in different countries.
